A potentially game-changing Alzheimer’s therapy is to undergo clinical trials in America.

Pre-clinical studies carried out by M3 Biotechnology, headquartered in Seattle, of its NDX-1017 drug, showed it could ‘stop or slow’ the progression of the disease.

“Current drugs on the market for Alzheimer’s patients offer only symptomatic relief, whereas we anticipate NDX-1017 will slow, halt and potentially restore lost function. The pre-clinical studies suggest we are on the right path, and we are excited to advance a much-needed brain regenerative therapy to alleviate the suffering of millions afflicted by the disease, and their families, around the world,” said M3 CEO Leen Kawas.